Medicover GmbH

Munich 20 trials 8 recruiting

20 Registered trials

8 Currently recruiting

Organisation

Medicover GmbH

Location

Munich, Germany

Identifier

ORG-100051136

Address

Orleansplatz 3, Au-Haidhausen, 81667, Germany

Departments

#3562 : Medicover München Ost MVZ
#40815: Medicover MVZ München Ost-Rheumatologie
#40815:Medicover MVZ München Ost-Rheumatologie
Medicover München Ost MVZ
Medicover GmbH, Medicover München Ost MVZ
Medicover Muenchen Ost MVZ
Medicover München Ost MVZ
N/A
Neuroendokrinologie
Rheumatologie

Clinical trials at this site (20)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting

2025-520831-18-00 Primary Sjogren’s Disease 4 2025-12-12
A clinical study of tulisokibart to treat radiographic axial spondyloarthritis (MK-7240-013) Recruiting

2025-521059-21-00 Radiographic axial spondyloarthritis (as known as ankyl 4 2025-11-25
A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Recruiting

2025-521745-25-00 Rheumatoid Arthritis 4 2025-11-06
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Systemic lupus erythematosus (SLE) 5 2024-11-28
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes 5 2025-08-15
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended

2023-508499-12-00 Systemic Lupus Erythematosus 5 2023-05-17
A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N… Ended

2023-505696-74-00 systemic lupus erythematosus 5 2022-02-10
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 5 2022-09-21
A trial to assess the long-term safety of octreotide subcutaneous depot in patients with acromegaly Ended

2024-510667-33-00 Acromegaly 5 2021-06-03
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i… Ended

2024-512986-15-00 Sjögren’s Disease 4